142 related articles for article (PubMed ID: 8475668)
21. [Autologous bone marrow transfusion in the treatment of adults with hematologic neoplasms. Experiences from Bern].
Brun del Re GP; Tschopp L; Cerny T; Bucher U
Schweiz Med Wochenschr; 1989 Jun; 119(25):902-10. PubMed ID: 2667130
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy with interleukin-2 after autologous bone marrow transplantation for hematologic malignancies.
Benyunes MC; Thompson JA; York A; Buckner CD; Fefer A
Prog Clin Biol Res; 1994; 389():229-38. PubMed ID: 7700905
[No Abstract] [Full Text] [Related]
23. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
[TBL] [Abstract][Full Text] [Related]
24. Recombinant interleukin-2 treatment before and after autologous stem cell transplantation in hematologic malignancies: clinical and immunologic effects.
De Laurenzi A; Iudicone P; Zoli V; De Rosa L; Guglielmetti M; Pescarollo A; Papetti C; Pacilli L; Lapponi P; Petti N
J Hematother; 1995 Apr; 4(2):113-20. PubMed ID: 7633841
[TBL] [Abstract][Full Text] [Related]
25. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual disease.
Bosly A; Brice P; Humblet Y; Doyen C; Faille A; Chatelain B; Franks C; Gisselbrecht C; Symann M
Nouv Rev Fr Hematol (1978); 1990; 32(1):13-6. PubMed ID: 2349079
[TBL] [Abstract][Full Text] [Related]
27. [Bone marrow autotransplantation in acute myeloblastic leukemia in its first complete remission. The clinical results in 41 patients].
Tomás JF; Gómez-García de Soria V; Pinilla I; Lamana M; Figuera A; Arranz R; Cámara R; Fernández-Villalta MJ; Alegre A; Fernández-Rañada JM
Med Clin (Barc); 1997 Feb; 108(6):201-6. PubMed ID: 9102484
[TBL] [Abstract][Full Text] [Related]
28. Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease.
Foa R; Fierro MT; Cesano A; Guarini A; Bonferroni M; Raspadori D; Miniero R; Lauria F; Gavosto F
Blood; 1991 Aug; 78(4):1041-6. PubMed ID: 1868239
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines.
Slavin S; Ackerstein A; Weiss L; Nagler A; Or R; Naparstek E
Cancer Invest; 1992; 10(3):221-7. PubMed ID: 1581831
[TBL] [Abstract][Full Text] [Related]
30. [Allogenic bone marrow transplantation versus autograft in acute lymphoblastic leukemia, in second remission in 113 children. Results of the Grupo Español de Transplante de Medula Niños (GETMON)].
Badell I; Ortega JJ; Muñoz A; Bureo E; Madero L; Olivé T; Cubells J; Maldonado MS; Baro J; Díaz MA
Sangre (Barc); 1996 Apr; 41(2):101-8. PubMed ID: 9045349
[TBL] [Abstract][Full Text] [Related]
31. Lymphokine-activated killer (LAK) cells and cytokines synergize to kill clonal cells in acute myeloid leukemia (AML) in vitro.
Braun S; Gerhartz HH; Schmetzer HM
Haematologia (Budap); 2000; 30(4):271-88. PubMed ID: 11204027
[TBL] [Abstract][Full Text] [Related]
32. Influence of cytokines and autologous lymphokine-activated killer cells on leukemic bone marrow cells and colonies in AML.
Braun SW; Gerhartz HH; Schmetzer HM
Acta Haematol; 2001; 105(4):209-21. PubMed ID: 11528095
[TBL] [Abstract][Full Text] [Related]
33. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
34. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia.
Bergmann L; Heil G; Kolbe K; Lengfelder E; Puzicha E; Martin H; Lohmeyer J; Mitrou PS; Hoelzer D
Leuk Lymphoma; 1995 Jan; 16(3-4):271-9. PubMed ID: 7719235
[TBL] [Abstract][Full Text] [Related]
36. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.
Blaise D; Attal M; Reiffers J; Michallet M; Bellanger C; Pico JL; Stoppa AM; Payen C; Marit G; Bouabdallah R; Sotto JJ; Rossi JF; Brandely M; Hercend T; Maraninchi D
Eur Cytokine Netw; 2000 Mar; 11(1):91-8. PubMed ID: 10705305
[TBL] [Abstract][Full Text] [Related]
37. Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow.
Almici C; Manoni L; Carlo-Stella C; Garau D; Cottafavi L; Rizzoli V
Bone Marrow Transplant; 1995 Jul; 16(1):95-101. PubMed ID: 7581136
[TBL] [Abstract][Full Text] [Related]
38. Detection of minimal residual disease in patients with childhood common acute lymphoblastic leukemia after autologous bone marrow transplantation with ex vivo purging and systemic IL-2 infusion: unsuccessful prediction of subsequent relapse.
Kiyoi H; Kojima S; Kato K; Matsuyama T; Kodera Y; Ohno R; Naoe T
Bone Marrow Transplant; 1995 Sep; 16(3):437-42. PubMed ID: 8535317
[TBL] [Abstract][Full Text] [Related]
39. High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study.
Pardo N; Martí F; Fraga G; Illa J; Badell I; Peiró M; Bertran E; García J; Rueda F; Cubells J
Med Pediatr Oncol; 1996 Dec; 27(6):534-9. PubMed ID: 8888813
[TBL] [Abstract][Full Text] [Related]
40. Lymphokine-activated killer (LAK) cell purging of bone marrow.
Cramer DV; Long GS
Prog Clin Biol Res; 1990; 333():125-35; discussion 136-7. PubMed ID: 2308977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
